NCI Director Monica Bertagnolli delivers her first public speech at the ECOG-ACRIN Cancer Research Group meeting
Leaders and members of the ECOG-ACRIN Cancer Research Group were honored to be the recipients of the first public address of Monica Bertagnolli, MD, as National Cancer Institute Director
NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib
Arm Z1K of NCI-MATCH met its primary endpoint, with ipatasertib demonstrating clinically significant activity in patients, warranting additional studies
S/N1806 Toxicity Data: No Safety Concerns
An interim toxicity assessment on the largest cancer trial in North America investigating bladder-preserving therapy finds no safety concerns
Radiotherapy and Recurrence in RxPONDER Trial
Do patients with low-risk breast cancer need regional node irradiation? Analysis of RxPONDER data suggests a dedicated clinical trial is needed to learn the answer
Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials to develop and validate multi-modal intelligence models that could outperform the National Comprehensive Cancer Network in the prediction of distant metastasis and other outcomes
NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research
Radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival, and led to significantly higher rates of locoregional failure, when compared to RT + cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma that have a contraindication to cisplatin
Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer
Treating patients with early-stage, high-risk breast cancer with a supplemental radiation boost to the surgical cavity concurrently during hypo-fractionated whole breast irradiation for a 3-week treatment course was not considered inferior to treating patients over several weeks with conventional whole breast irradiation and a sequential boost following lumpectomy
The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival
Clinical trial NRG-RTOG 1112 demonstrated that adding stereotactic body radiation therapy to treatment with sorafenib improved overall survival
Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting to assess the stage of disease more accurately using standard CT scans
A customized deep learning algorithm using standard CT scan images and associated data contributed by patients who participated in the E3311 phase 2 trial shows promise, especially for patients with a new diagnosis of HPV-related head and neck cancer
ECOG-ACRIN taps the University of Pennsylvania’s Selina Luger to lead its Leukemia Committee
Dr. Luger, a practicing hematologist-oncologist and internationally regarded acute leukemia and myeloid disorders researcher, is the newly appointed chair of the ECOG-ACRIN Cancer Research Group Leukemia Committee